XORTX Therapeutics Inc.’s Post

Improving plasmid DNA is essential for advancing CAR-T cancer therapies. In our latest viewpoints article, Venkata Shravan K Indurthi clearly explains how these innovations boost manufacturing efficiency and support scientific advances, expanding treatment options for cancer patients. #CARTTherapy #GeneTherapy #PlasmidDNA https://lnkd.in/gRn3tSQi

📢Patient Reported Outcomes from the #OlympiA trial: #Olaparib (OL) vs. placebo (PL) in high-risk early breast cancer patients with germline BRCA1/2 mutations. 🔸OL led to statistically significant but not clinically meaningful greater fatigue at 6 & 12 months (P < .05). 🔸No significant differences at 18 & 24 months. 🔸NV severity was worse in patients treated with OL compared to PL at both 6 months and 12 months. More insights on treatment-emergent symptoms and functional scores in the full report. https://ow.ly/oOX050QCeox

🌿 Exciting breakthrough in cancer research! This study unveils the potent cytotoxic activity of A. catechu seed extract against oral squamous carcinoma cells. 💊 These findings suggest a promising avenue for developing novel therapeutic strategies against this challenging disease. #CancerResearch #Apoptosis #TherapeuticInnovation 📊🔬

 BREAKTHROUGH in Breast Cancer Treatment!  A new anti-fibrotic drug shows promise for treating HER2-negative breast cancer, a common and challenging type of the disease. Researchers have identified fibrosis as a key factor in disease progression, and combining the new drug with traditional therapies could significantly improve patient outcomes. Find out how this discovery could change the future of cancer care. Read more: https://lnkd.in/djuRD2NX #BreastCancerResearch #HER2Negative #MedicalBreakthrough #TargetedTherapy #Fibrosis #HealthCareInnovation #OncologyResearch #PersonalizedMedicine #CancerCare #LifeSciences #MedicalAdvancements #CancerTreatment #ClinicalResearch #Nintedanib #HealthNews

Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. https://ow.ly/nEeI50SyTve

Inducing Immunogenic Cancer Cell Death through Novel Photodynamic Therapy https://lnkd.in/dqU3jP3V

The book discuss the new advances in diagnosis and management of pancreatic cancer

Nicotine and Cancer Risk # 5 My ongoing series showing what Big Tobacco doesn’t want to to know, that nicotine promotes cancer. “Brain metastasis is the most common malignancy of the central nervous system, occurring in up to 50% of lung cancer patients with a median survival of less than a year and at a rate twice to ten times higher than that of primary neural neoplasms." "Here, we showed that nicotine skews neutrophil polarization within the pre-metastatic brain niche and promotes metastatic colonization of lung cancer cells by regulating their stemness and energy metabolism." (Oncogene 2022) https://lnkd.in/gKrkQ97F #wigmoreonnicotine

We are pleased to announce that the FDA has granted Fast Track designation for IMM-1-104 for the treatment of patients with pancreatic ductal adenocarcinoma (#PDAC). With IMM-1-104, our lead product candidate, we are leveraging deep cyclic inhibition to target tumors with RAS driven mutations, including pancreatic cancer, considered the most RAS-addicted of all cancers. Read more: https://buff.ly/4bIxdsK #pancreatic #PancreaticCancerResearch #KRASmutations #RASmutations #TargetedOncology #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #MetastaticCancer #AdvancedCancer 

Ki-67 may be a useful prognostic tool for identifying early breast cancer patients with at high risk of recurrence. Follow our account to learn more about Ki-67 and other prognostic biomarkers.